Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR +/ HER2 ‐Negative Breast Cancer: A Real‐World Study
Cancer Medicine · 2026
DOI: 10.1002/cam4.72208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Franciele Hinterholz Knebel und 26 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Drug Resistance, Neoplasm, Lung Neoplasms, Breast Neoplasms. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Ludwig Institute for Cancer Research, Sociedade Beneficente de Senhoras Hospital Sírio-Libanês.
Abstract (Originalsprache)
Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell lung cancer (NSCLC) and breast cancer (MBC). This real‐world, longitudinal study included 48 metastatic patients (42 with EGFR ‐mutant NSCLC; 6 with HR+/HER2‐negative MBC) treated at a Brazilian oncology reference center. Serial plasma samples were analyzed by ddPCR for activating and resistance mutations at specific time points. In the NSCLC cohort, EGFR T790M was detected in 48.4% of patients who progressed on 1st/2nd‐generation TKIs. For patients on 3rd‐generation TKIs, EGFR C797S was the main AR mechanism (47%), followed by PIK3CA , BRAF mutations, and ERBB2 / EGFR amplifications. Longitudinal analysis anticipated radiological progression by approximately 5 months. Early molecular response, characterized by mutation clearance, preceded radiological response. In the MBC cohort, hotspot ESR1 mutations (D538G, L536R, Y537S) were identified in 50% of patients. Variations in ctDNA fractional abundance predicted disease progression up to 9 months before radiological confirmation. This study provides real‐world evidence that ddPCR‐based ctDNA monitoring enables early detection of resistance and predicts disease progression significantly earlier than standard imaging in both NSCLC and MBC. Despite the limited sample size, particularly in the MBC cohort, these real‐world findings support liquid biopsy as a minimally invasive tool with the potential to guide therapeutic decisions and inform personalized management in precision oncology. Larger prospective studies are needed to confirm these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
- Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
- Bioinformatics Team, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
- Translational Oncogenomics Lab, The Institute of Cancer Research, London, UK.
ORCID-Profile: Maurício Fernando Silva Almeida Ribeiro, Rudinei Diogo Marques Linck, Isabela Flauzino Ferreira, Cibele Masotti, Rodrigo Saddi, Karina Perez Sacardo, Leandro Jonata Carvalho Oliveira, Daniele Coelho Duarte, Paula Fontes Asprino, Elisângela Monteiro Coser, Andrea Kazumi Shimada, Olavo Feher, Max Senna Mano, Artur Katz, Anamaria Aranha Camargo, Fabiana Bettoni
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Ludwig Institute for Cancer Research
- Sociedade Beneficente de Senhoras Hospital Sírio-Libanês
- Virginia and D.K. Ludwig Fund for Cancer Research
Zitieren
APA
Knebel, F. H., Ribeiro, M. F. S. A., Linck, R. D. M., Ferreira, I. F., Masotti, C., Saddi, R., Sacardo, K. P., Canedo, F. S. N. A., Oliveira, L. J. C., Duarte, D. C., Asprino, P. F., Dos Santos, E. X., Coser, E. M., Kleftogiannis, D., Barber, L. J., Gerlinger, M., Alessi, J. V. M., Shimada, A. K., Santini, F. C., …, & Bettoni, F. (2026). Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR +/ HER2 ‐Negative Breast Cancer: A Real‐World Study. Cancer Medicine. https://doi.org/10.1002/cam4.72208
Vancouver
Knebel FH, Ribeiro MFSA, Linck RDM, Ferreira IF, Masotti C, Saddi R, et al. Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR +/ HER2 ‐Negative Breast Cancer: A Real‐World Study. Cancer Medicine. 2026. doi:10.1002/cam4.72208
BibTeX
@article{Knebel2026,
author = {Knebel, Franciele Hinterholz and Ribeiro, Maurício Fernando Silva Almeida and Linck, Rudinei Diogo Marques and Ferreira, Isabela Flauzino and Masotti, Cibele and Saddi, Rodrigo and Sacardo, Karina Perez and Canedo, Felipe Sales Nogueira Amorim and Oliveira, Leandro Jonata Carvalho and Duarte, Daniele Coelho and Asprino, Paula Fontes and Dos Santos, Ernande Xavier and Coser, Elisângela Monteiro and Kleftogiannis, Dimitrios and Barber, Louise J and Gerlinger, Marco and Alessi, João Victor Machado and Shimada, Andrea Kazumi and Santini, Fernando Costa and de Souza, Ciro Eduardo and Feher, Olavo and Junior, Gilberto de Castro and Costa, Frederico Perego and Mano, Max Senna and Katz, Artur and Camargo, Anamaria Aranha and Bettoni, Fabiana},
title = {Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR +/ HER2 ‐Negative Breast Cancer: A Real‐World Study},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72208}
}
EUVIMED